Literature DB >> 2360795

Which risk factors predict the levodopa response in fluctuating Parkinson's disease?

M W Horstink1, J C Zijlmans, J W Pasman, H J Berger, J J Korten, M A van 't Hof.   

Abstract

Three putative risk factors to the pathogenesis of end-of-dose-related fluctuations--severity of Parkinson's disease (PD), duration of PD, and duration of levodopa therapy--were evaluated in 39 patients with PD by measuring response duration and response magnitude to a single levodopa dose. After discontinuing levodopa therapy for 12 hours, the motor status of each patient was assessed before a single dose of 100 mg of levodopa plus 25 mg of decarboxylase inhibitor was given and at five 45-minute intervals thereafter. Multiple regression analysis showed that the response duration was best predicted by the severity of PD. The response magnitude was significantly correlated both to the duration of PD and to the duration of levodopa therapy. It is argued, however, that the response magnitude was predicted by the duration of levodopa therapy. Our results are in accordance with those of other recent studies and indicate that variances in levodopa response duration and in levodopa response magnitude are caused by their own differential risk factor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360795     DOI: 10.1002/ana.410270514

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Authors:  H M Bryson; R J Milne; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 3.  Comparative tolerability of the newer generation antiparkinsonian agents.

Authors:  D Lambert; C H Waters
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 4.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

5.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

Authors:  M Rodriguez; G Lera; J Vaamonde; M R Luquin; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

6.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Authors:  J L Montastruc; O Rascol; J M Senard; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 7.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.